- Home
- SNDX vs GAM Comparison
SNDX vs GAM Comparison
Compare SNDX & GAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNDX
- GAM
- Stock Information
- Founded
- SNDX 2005
- GAM 1927
- Country
- SNDX United States
- GAM United States
- Employees
- SNDX N/A
- GAM N/A
- Industry
- SNDX Biotechnology: Pharmaceutical Preparations
- GAM Investment Managers
- Sector
- SNDX Health Care
- GAM Finance
- Exchange
- SNDX Nasdaq
- GAM Nasdaq
- Market Cap
- SNDX 1.3B
- GAM 1.5B
- IPO Year
- SNDX 2016
- GAM N/A
- Fundamental
- Price
- SNDX $13.51
- GAM $63.51
- Analyst Decision
- SNDX Strong Buy
- GAM
- Analyst Count
- SNDX 11
- GAM 0
- Target Price
- SNDX $38.55
- GAM N/A
- AVG Volume (30 Days)
- SNDX 3.3M
- GAM 20.1K
- Earning Date
- SNDX 11-03-2025
- GAM 01-01-0001
- Dividend Yield
- SNDX N/A
- GAM 5.74%
- EPS Growth
- SNDX N/A
- GAM N/A
- EPS
- SNDX N/A
- GAM 11.67
- Revenue
- SNDX $77,933,000.00
- GAM N/A
- Revenue This Year
- SNDX $629.90
- GAM N/A
- Revenue Next Year
- SNDX $114.74
- GAM N/A
- P/E Ratio
- SNDX N/A
- GAM $3.95
- Revenue Growth
- SNDX 2126.66
- GAM N/A
- 52 Week Low
- SNDX $8.58
- GAM $37.32
- 52 Week High
- SNDX $22.50
- GAM $46.48
- Technical
- Relative Strength Index (RSI)
- SNDX 36.63
- GAM 64.30
- Support Level
- SNDX $13.00
- GAM $62.25
- Resistance Level
- SNDX $15.79
- GAM $63.99
- Average True Range (ATR)
- SNDX 1.10
- GAM 0.89
- MACD
- SNDX -0.26
- GAM -0.06
- Stochastic Oscillator
- SNDX 13.82
- GAM 64.49
About SNDX Syndax Pharmaceuticals Inc.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.
About GAM General American Investors Inc.
General American Investors Co Inc is a closed-end, diversified management investment company. The primary investment objective of the company is long-term capital appreciation through investment in companies with above-average growth potential. It focuses on equity securities with growth potential at reasonable valuations.